Altimmune Inc (ALT) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Fortification [Yahoo! Finance]
Altimmune, Inc. (ALT)
NASDAQ:AMEX Investor Relations:
altimmune.com/investors
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus R&D Expense: $18.4 million in Q4 2025, down from $19.8 million in Q4 2024. G&A Expense: $10.5 million in Q4 2025, up from $5.1 million in Q4 2024. Net Loss: $27.4 million or $0.27 per share in Q4 2025, compared to $23.2 million or $0.33 per share in Q4 2024. Cash Position: $274 million at year-end 2025. Pro Forma Cash Position: Approximately $340 million after January 2026 capital raise. Capital Raise: $75 million in January 2026 from a registered direct offering. Operating Cash Runway: Expected to extend into 2028. Warning! GuruFocus has detected 2 Warning Signs with ALT. Is ALT fairly valued? Test your thesis with our free DCF calculator. Release Date: March 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Altimmune Inc ( NASDAQ:ALT ) has received FDA Breakthrough Therapy designation for pemvidutide in MASH, indicating its potential for subs
Show less
Read more
Impact Snapshot
Event Time:
ALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALT alerts
High impacting Altimmune, Inc. news events
Weekly update
A roundup of the hottest topics
ALT
News
- Altimmune (ALT) had its "market perform" rating reaffirmed by William Blair.MarketBeat
- Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
- Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business UpdatesGlobeNewswire
- Altimmune to Participate in Upcoming Investor ConferencesGlobeNewswire
- Altimmune to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026GlobeNewswire
ALT
Earnings
- 3/5/26 - Miss
ALT
Sec Filings
- 3/5/26 - Form 8-K
- 2/27/26 - Form 4
- 2/27/26 - Form 4
- ALT's page on the SEC website